Navigation Links
Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
Date:2/19/2013

Researchers at the Moffitt Cancer Center have found a potential mechanism by which immune suppressive myeloid-derived suppressor cells can prevent immune response from developing in cancer. This mechanism includes silencing the tumor suppressor gene retinoblastoma 1 or Rb1. Their data explains a new regulatory mechanism by which myeloid-derived suppressor cells are expanded in cancer.

Their study appeared in a recent issue of Nature Immunology.

According to the authors, two kinds of myeloid-derived suppressor cells - monocytic M-MDSCs and granulocytic PMN-MDSCs - regulate immune responses in cancer and other conditions. In experiments with tumor-bearing mice, they discovered that M-MDSCs acquire some of the physical characteristics of PMN-MDSCs. Acquisition of the PMN-MDSCs characteristics, they found, was "mediated" by the silencing of Rb1 by modifications in a histone deacetylase 2 (HDAC-2), an enzyme decoded by the HDAC2 gene.

"Our findings demonstrate the function of a newly discovered regulatory mechanism of myeloid cells in cancer," said study lead author Dmitry I. Gabrilovich, M.D., senior member of Moffitt's Immunology Program.

According to study first author Je-In Youn, Ph.D., a post-doctoral fellow in the Gabrilovich laboratory, Rb1 is among members of the retinoblastoma family of transcription regulators that integrate multiple cellular signals to control cell proliferation and differentiation. In their experiments, the researchers found that when Rb1 was deficient in tumor-bearing mice it indicated a direct role for Rb1 in regulating M-MDSC differentiation toward PMN-MDSCs.

Their data suggested that Rb1 silencing could be initiated by HDAC-2 which, said Youn, is known to be involved in modulating the repressive activity on promoters of certain genes involved in cell differentiation.

They proposed that, in tumors, a large portion of M-MDSCs acquire the ability to differentiate into PMN-MD
'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
(Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
(Date:11/27/2014)... 27, 2014 Developers and plugin specialist of ... entitled ProPip, taking FCPX to the next level. , “ProPip ... a few clicks of a mouse,” said Christina Austin, CEO ... our users will appreciate.” , With ProPip users can show ... possibilities truly endless. ProPip is great for commentaries, news casting, ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
(Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... have, for the first time, taken adult stem cells and ... human jaw.They say the groundbreaking work may one day //lead ... suffer from temporomandibular disorders. ,The study started with ... these cells can be coaxed to become any other type ...
... the last half century, and officials at the ... be diagnosed with it this year.,The study, which analyzed ... ages of 30 and 50,// found what the researchers ... tanning can be dangerous to healthy skin. ,Melanoma ...
... and observational studies previously conducted in elderly populations ... were performed before intracoronary stents and use of ... Dr. Hanoch Hod, of Chaim Sheba Medical //Center ... consecutive patients aged 70 or older treated for ...
... hormone may help patients in treating a rare disorder ... metabolic abnormalities.The study's author found that the results of ... role of leptin in common metabolic conditions such as ... her colleagues found that a lab-engineered version of leptin, ...
... control to limit women's periods ,Seasonale, a new drug ... reduce the number of women's periods to four a year ... pills, but for longer spans of time.// ,Seasonale ... ,"For women who desire prevention of pregnancy and are comfortable ...
... milk chocolate, which is most commonly used in candy ... They found the same discouraging result among patients who ... suggest that milk and other dairy products somehow discourage ... chocolate. Only subjects who ate dark chocolate showed a ...
Cached Medicine News:Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Obesity Hormone -' Leptin' may treat Metabolic Disorder 2Health News:New birth control to limit women's periods 2Health News:When it comes to health, all chocolates not the same. 2
(Date:11/26/2014)... 2014  Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... The public is welcome to participate in ... BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray 2014 ... Time Location: Palace Hotel, New York CityEvent:Oppenheimer ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... Company"), a clinical stage biopharmaceutical company that engages ... for the treatment of inflammatory diseases and cancer, ... underwritten public offering of 3,450,000 units, with each ... common stock, par value $0.0001 per share, and ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2
This radiolucent One-piece fixator permits independent mechanical adjustments of the following: Distraction/Compression, Dorsal/Palmar Translation, Radial/Ulnar Translation, Flexion/Extension....
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
... the Pennig Minifixator, combines the advantage of secure ... tissue dissection is not necessary, since in general, ... fixation in the hand has required bridging of ... (Asche and Burny) because of the design of ...
Medicine Products: